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ABSTRACT
Objectives: This study was undertaken to test the
extent to which a new antibiotic prophylaxis regimen
for percutaneous endoscopic gastrostomy (PEG),
identified as a justified and simpler alternative to
conventional regimen in a randomised clinical trial, has
been adopted in clinical practice.
Design: A Swedish nationwide implementation survey,
conducted in February 2013, assessed the level of
clinical implementation of a 20 ml dose of oral solution
of sulfamethoxazole and trimethoprim deposited in the
PEG catheter immediately after insertion. All hospitals
inserting at least five PEGs annually were identified
from the Swedish Patient Registry. A clinician involved
in the PEG insertions at each hospital participated in a
structured telephone interview addressing their routine
use of antibiotic prophylaxis.
Setting: All Swedish hospitals inserting PEGs (n=60).
Participants: Representatives of PEG insertions at
each of the 60 eligible hospitals participated (100%
participation).
Main outcome measures: Use of routine antibiotic
prophylaxis for PEG.
Results: A total of 32 (53%) of the 60 hospitals had
adopted the new regimen. It was more frequently
adopted in university hospitals (67%) than in
community hospitals (41%). An annual total of 1813
(70%) of 2573 patients received the new regimen.
Higher annual hospital volume was associated with a
higher level of adoption of the new regimen (80% in
the highest vs 31% in the lowest).
Conclusions: The clinical implementation of the new
antibiotic prophylaxis regimen for PEG was high and
rapid (70% of all patients within 3 years), particularly
in large hospitals.
INTRODUCTION
A main goal of clinical research is to improve
clinical practice. Yet, evaluations of the
implementation of novel research ﬁndings
are rare and the methodological quality of
the existing literature is limited.1 The process
from revealing a clinically relevant research
ﬁnding to having it adopted in the clinical
setting is often difﬁcult and requires
resources and directed implementation strat-
egies.2–4 Many patients do not receive appro-
priate care or receive unnecessary or
harmful treatments.5 This study was under-
taken to evaluate the potential clinical imple-
mentation of a new antibiotic prophylaxis
regimen used to reduce infectious complica-
tions after the insertion of percutaneous
endoscopic gastrostomy (PEG) for enteral
nutrition in patients with eating difﬁculties,
as recommended in a randomised clinical
trial published in 2010.6 The new regimen
was a 20 ml dose of the oral solution of sulfa-
methoxazole and trimethoprim deposited in
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the PEG catheter immediately after its insertion. This
regimen was tested against a standard of an intravenous
dose of 1.5 g cefuroxime administered 1 h before insert-
ing PEG. The trial included 234 patients (116 with the
new regimen and 118 with standard regimen), and all
patients and evaluators were blinded to which prophy-
laxis was used. The study outcome was clinical signs of
infection, supported by bacterial cultures and blood
tests. The trial was a non-inferiority study, that is, if the
new regimen was at least as effective as standard treat-
ment it would be preferable since it had advantages that
favoured its use, that is, easier to administer, cheaper,
not given unnecessarily to the 10% of the cases where
PEG is not possible to insert.7 8 The trial showed that
the new regimen was at least as effective in preventing
infections, and the results were published as an original
article in BMJ.6 We hypothesised that the trial had
changed clinical practice and tested this hypothesis in a
nationwide Swedish survey.
METHODS
Presentation of the trial results
The trial that was assessed in this study was published in
BMJ in 2010.6 Moreover, a summary of the study was
published in the Swedish Medical Journal
(Lakartidningen). An oral presentation of the trial was
conducted at a National Swedish conference in surgery.
Finally, the study was presented at a Swedish meeting for
clinicians with an interest in PEG.
Study design and setting
This was a population-based, nationwide Swedish imple-
mentation survey. All hospitals that had conducted an
average of at least ﬁve PEG insertions/year during the
3-year period 2009–2011 were identiﬁed from the
Swedish Patient Registry. This registry is complete
nationwide and collects data of all diagnoses and surgi-
cal procedures (including endoscopic procedures)
during in-hospitalisations or specialist outpatient care,
and has been found to have excellent completeness and
accurateness.9 A project nurse contacted the clinician
responsible for the PEG activities at each of the identi-
ﬁed hospitals and conducted a structured telephone
interview strictly according to a study questionnaire.
There was no mention about the trial under study until
after the questions about current antibiotic prophylaxis
were completed. All interviews were completed during
the period from 30 January to 28 February 2013. The
fact that the test regimen was entirely new facilitated the
assessment of its potential implication in the clinical
setting. The study was approved by the Regional Ethical
Review Board in Stockholm, Sweden.
Statistical analyses
The hospitals were categorised into three groups:
(1) university hospitals, (2) county hospitals or (3) com-
munity hospitals. We also estimated the number of
inserted PEGs for 2012. This was performed by calculat-
ing the arithmetic mean of the number of inserted
PEGs during the 3-year period 2009–2011 according to
the Swedish Patient Registry for each hospital, and then
summarised for all patients. Furthermore, we stratiﬁed
all patients in 2012 by the use of antibiotic regimen, and
in a similar way stratiﬁed each category of hospital. An
additional categorisation of the hospitals into quintiles,
based on the ranking of each hospital according to the
estimated mean number of patients, was also conducted.
The data management and the diagrams were con-
ducted using the SAS (V.9.2; SAS Institute Inc, Cary,
North Carolina, USA).
RESULTS
There were 60 eligible hospitals in Sweden that inserted
at least 5 PEGs/year. All these hospitals participated in
the interviews (100% participation rate). A total of 17
(28%) hospitals did not routinely use any antibiotic
prophylaxis, most being community hospitals (71%).
The rates of implementation of the new regimen at all
hospitals and at the three categories of hospitals are pre-
sented in table 1. The total number of hospitals which
had implemented the new regimen was 32 (53%);
among hospitals using antibiotic prophylaxis, this rate
was 32 out of 43 (74%). The new regimen was most fre-
quently adopted in university hospitals (67%), while it
was less commonly adopted in community hospitals
(41%). Of all hospitals that had introduced the new
regimen, 25 (78%) had adopted the new regimen
within the year 2011. Reasons for having changed to the
new regimen are presented in table 1. The most
common reason was having read the article published in
BMJ (63%).
Translated to the number of patients, an annual total
of 1813 (70%) of 2573 patients received the new
regimen (ﬁgure 1, table 2). Excluding hospitals not
using antibiotic prophylaxis, the frequency using the
new regimen was 79%. A higher annual hospital volume
was associated with an increased adoption of the new
regimen; the frequency of use of the new regimen was
31% in the lowest quintile of hospitals and 80% in the
highest (table 2). The distribution of antibiotic prophy-
laxis according to the number of patients treated at the
three categories of hospitals showed a higher frequency
of the new regimen in university hospitals (84%), fol-
lowed by county hospitals (71%) and community hospi-
tals (45%; ﬁgure 2).
DISCUSSION
This study shows that the new antibiotic prophylaxis,
with a solution of sulfamethoxazole and trimethoprim
given directly in the newly inserted PEG, had replaced
standard prophylaxis with intravenously given antibiotics
to a considerable extent in Sweden.
Methodological strengths of the study include the
ability to identify all hospitals inserting PEGs in Sweden
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through the Patient Registry, making it population-based
in design and reducing the risk of selection bias. The
100% complete inclusion of all eligible hospitals further
counteracted biased selection. Finally, the use of struc-
tured telephone interviews to collect the data should
minimise the misclassiﬁcation of the information col-
lected. These advantages should provide high internal
validity of the study.1 The external validity, however, is
uncertain since it is unknown whether the results in
Sweden are representative of those of other countries.
The trial being followed up was conducted in Sweden,
which should facilitate its implementation in this
country in particular, while the implementation in other
countries might be more limited.
Scientiﬁc evidence suggests that enabling research
ﬁndings to change clinical practice requires comprehen-
sive approaches and effective strategies at different
levels, tailored to speciﬁc settings and target groups.3–5
The present study shows that it is possible to inﬂuence
clinical practice based on a single randomised clinical
trial if the results are convincing and easy to adopt in
routine care. The implementation of the new regimen
tested in the present study was facilitated by the fact that
it had practical advantages and was cheaper to use com-
pared with the standard regimen. In other trials, the
tested treatment might often be more complex to use
and more costly, which might make its introduction into
routine clinical use less likely. For example, another
implementation study of an endoscopic procedure was a
large cohort study in the USA which showed that low
rates of duodenal biopsy remained in more recent calen-
dar periods in patients with clinical indications for
biopsy to identify coeliac disease despite clinical recom-
mendations to conduct such biopsies more frequently.10
University hospitals and PEG high-volume hospitals
were clearly more likely to adopt the new regimen com-
pared with smaller hospitals. This might be due to a
higher academic interest and a higher interest in the
PEG procedure, respectively, which might increase the
Table 1 Use of antibiotic regimen as part of the insertion of percutaneous endoscopic gastrostomy in Sweden, presented as
number of hospitals and hospitals divided by the three hospital categories community hospitals, county hospitals and
university hospitals
All hospitals Hospital category
(n=60) Community (n=27) County (n=24) University (n=9)
Number Per cent Number Per cent Number Per cent Number Per cent
Antibiotic prophylaxis regimen
New* 32 53 11 41 15 63 6 67
Other† 11 18 4 15 5 21 2 22
None 17 28 12 44 4 17 1 11
Knowledge of the trial
Yes 38 63 12 44 18 75 8 89
No 22 37 15 56 6 25 1 11
Hospitals using the new regimen
Year of introduction
2010 10 31 2 7 7 29 1 11
2011 15 47 4 15 7 29 4 44
2012 7 22 5 19 1 4 1 11
Reason for introduction
Read the article 20 63 5 45 9 60 6 100
Scientific meeting 7 22 3 27 4 27 0 0
Colleague 4 13 2 18 2 13 0 0
Unknown 1 3 1 9 0 0 0 0
*20 ml dose of oral solution of sulfamethoxazole and trimethoprim deposited in the PEG catheter immediately after insertion.
†Intravenously administered antibiotics before percutaneous endoscopic gastrostomy insertion.
Figure 1 Use of antibiotic regimen as part of the insertion of
percutaneous endoscopic gastrostomy in Sweden, presented
as number of patients. New regimen: 20 ml dose of oral
solution of sulfamethoxazole and trimethoprim deposited in
the percutaneous endoscopic gastrostomy (PEG) catheter
immediately after insertion. Other regimen: intravenously
administered antibiotics before PEG insertion.
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likelihood of reading scientiﬁc articles and willingness to
adopt new treatments. The lack of use of any antibiotic
prophylaxis was not negligible, which might not be
entirely justiﬁed considering the amount of evidence
showing a high risk of infectious complications,11 and an
absolute risk reduction of such complications by 14–
17% with the use of antibiotic prophylaxis.7 8
Although it is pleasing to ﬁnd such rapid and positive
uptake of an innovation, any recommendation for
uptake of this new practice should be made with caution
since it is based on one clinical trial of 200 patients only.
A systematic review, which incorporates multiple sources
of evidence, might provide a stronger basis for changing
clinical practice.
In conclusion, this nationwide complete Swedish
survey provides encouraging evidence of a high (53% of
all hospitals and 70% of all patients) and rapid clinical
implementation of a new antibiotic prophylaxis regimen
for PEG based on the results of one well-designed rando-
mised clinical trial. The level of adoption of the new
regimen was substantially higher in university hospitals
and PEG high-volume hospitals compared with smaller
hospitals. This should encourage further randomised
clinical trials addressing clinically relevant topics.
Acknowledgements We are grateful to the research nurse Isabella Linder
Rosén for conducting all interviews.
Contributors JL had the original idea to conduct this study. JL and PL
planned the study and completed the data collection. FM did the analyses,
tables and figures. JL made the first draft of the article, and PL and FM
contributed with input on the article writing. JL is responsible for the overall
content as guarantor. All authors have read and approved the final
manuscript.
Funding The Swedish Research Council (SIMSAM) and through the regional
agreement on medical training and clinical research (ALF) between Stockholm
County Council and Karolinska Institutet.
Competing interests None.
Ethics approval The study was approved by the Regional Ethical Review
Board in Stockholm, Sweden (diary number 2013/131-32).
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement Data sharing: full dataset and statistical code are
available from the corresponding author at jesper.lagergren@ki.se.
STROBE guidelines We followed the recommendation of the STROBE
guidelines for observational studies.
REFERENCES
1. Fan E, Laupacis A, Pronovost PJ, et al. How to use an article about
quality improvement. JAMA 2010;304:2279–87.
2. Gilbody S, Whitty P, Grimshaw J, et al. Educational and
organizational interventions to improve the management of
depression in primary care: a systematic review. JAMA
2003;289:3145–51.
3. Althabe F, Buekens P, Bergel E, et al. A behavioral intervention to
improve obstetrical care. N Engl J Med 2008;358:1929–40.
4. Bessen T, Clark R, Shakib S, et al. A multifaceted strategy for
implementation of the Ottawa ankle rules in two emergency
departments. BMJ 2009;339:b3056.
5. Grol R, Grimshaw J. From best evidence to best practice:
effective implementation of change in patients’ care. Lancet
2003;362:1225–30.
Figure 2 Use of antibiotic regimen as part of the insertion of
percutaneous endoscopic gastrostomy (PEG) in Sweden,
presented as number of patients, and divided by the three
hospital categories community hospitals, county hospitals and
university hospitals. New regimen: 20 ml dose of oral solution
of sulfamethoxazole and trimethoprim deposited in the PEG
catheter immediately after insertion. Other: intravenously
administered antibiotics before PEG insertion.
Table 2 Use of antibiotic regimen as part of the insertion of percutaneous endoscopic gastrostomy in Sweden, presented as
number of patients per year and hospital, divided in quintiles of hospital volume (12 hospitals in each quintile)
Antibiotic
prophylaxis
regimen
All Quintile
(n=2573) 1 (n=101) 2 (n=220) 3 (n=341) 4 (n=495) 5 (n=1417)
N Per cent N Per cent N Per cent N Per cent N Per cent N Per cent
New* 1813 70 31 31 115 52 202 59 335 68 1130 80
Other† 270 11 20 20 60 27 114 33 77 15 0 0
None 490 19 50 49 45 20 25 7 83 17 287 20
*20 ml dose of oral solution of sulfamethoxazole and trimethoprim deposited in the PEG catheter immediately after insertion.
†Intravenously administered antibiotics before PEG insertion.
PEG, percutaneous endoscopic gastrostomy.
4 Lagergren J, Mattsson F, Lagergren P. BMJ Open 2013;3:e003067. doi:10.1136/bmjopen-2013-003067
Implementation of new antibiotic prophylaxis after PEG
 group.bmj.com on July 4, 2013 - Published by bmjopen.bmj.comDownloaded from 
6. Blomberg J, Lagergren P, Martin L, et al. Novel approach to
antibiotic prophylaxis in percutaneous endoscopic gastrostomy
(PEG): randomised controlled trial. BMJ 2010;341:c3115.
7. Lipp A, Lusardi G. Systemic antimicrobial prophylaxis for
percutaneous endoscopic gastrostomy. Cochrane Database Syst
Rev (Online) 2006;(4):CD005571.
8. Lipp A, Lusardi G. A systematic review of prophylactic antimicrobials
in PEG placement. J Clin Nurs 2009;18:938–48.
9. Ludvigsson JF, Andersson E, Ekbom A, et al. External review and
validation of the Swedish national inpatient register. BMC Public
Health 2011;11:450.
10. Lebwohl B, Tennyson CA, Holub JL, et al. Sex and racial disparities
in duodenal biopsy to evaluate for celiac disease. Gastrointest
Endosc 2012;76:779–85.
11. Blomberg J, Lagergren J, Martin L, et al. Complications after
percutaneous endoscopic gastrostomy in a prospective study. Scand
J Gastroenterol 2012;47:737–42.
Lagergren J, Mattsson F, Lagergren P. BMJ Open 2013;3:e003067. doi:10.1136/bmjopen-2013-003067 5
Implementation of new antibiotic prophylaxis after PEG
 group.bmj.com on July 4, 2013 - Published by bmjopen.bmj.comDownloaded from 
doi: 10.1136/bmjopen-2013-003067
 2013 3: BMJ Open
 
Jesper Lagergren, Fredrik Mattsson and Pernilla Lagergren
 
endoscopic gastrostomy
prophylaxis regimen for percutaneous 
Clinical implementation of a new antibiotic
 http://bmjopen.bmj.com/content/3/5/e003067.full.html
Updated information and services can be found at: 
These include:
Data Supplement
 http://bmjopen.bmj.com/content/suppl/2013/05/24/bmjopen-2013-003067.DC1.html
"Supplementary Data"
References
 http://bmjopen.bmj.com/content/3/5/e003067.full.html#ref-list-1
This article cites 10 articles, 2 of which can be accessed free at:
Open Access
http://creativecommons.org/licenses/by-nc/3.0/legalcode
http://creativecommons.org/licenses/by-nc/3.0/ and 
compliance with the license. See:
work is properly cited, the use is non commercial and is otherwise in 
use, distribution, and reproduction in any medium, provided the original
Creative Commons Attribution Non-commercial License, which permits 
This is an open-access article distributed under the terms of the
service
Email alerting
the box at the top right corner of the online article.
Receive free email alerts when new articles cite this article. Sign up in
Collections
Topic
 (153 articles)Pharmacology and therapeutics   
 (70 articles)Nutrition and metabolism   
 (43 articles)Medical management   
 (254 articles)Health services research   
 (47 articles)Gastroenterology and hepatology   
 (117 articles)Evidence based practice   
 
Articles on similar topics can be found in the following collections
 http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
 http://journals.bmj.com/cgi/reprintform
To order reprints go to:
 http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
 group.bmj.com on July 4, 2013 - Published by bmjopen.bmj.comDownloaded from 
Notes
 http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
 http://journals.bmj.com/cgi/reprintform
To order reprints go to:
 http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
 group.bmj.com on July 4, 2013 - Published by bmjopen.bmj.comDownloaded from 
